Hot Investor Mandate 1: New $300 Million Fund Focuses on Early Stage Therapeutics

3 Aug

A venture capital firm backed by a China-based investment group was founded in 2017 and is based in San Francisco, CA. The firm closed its inaugural fund of $300M and is actively seeking new investment opportunities. The fund will make 15-20 investments in total with no set number of investments per year. The firm will be actively involved in their portfolio companies and will invest $15-20M over the life of the company. Initial check sizes will depend on the company’s stage of development and their needs prior to investment. The firm will invest mainly in USA-based companies but may invest up to 20% of the fund in companies based in Western Europe.

The firm is focused solely on early-stage therapeutics and will not consider opportunities in medical devices, diagnostics, healthcare services or healthcare IT. The firm is primarily interested in traditional therapeutic modalities – programs that aim to discover and develop small molecule, antibody/protein-based clinical candidates will be considered. The ideal stages of development would be anywhere from IND candidate (12-24 months from the clinic) through Phase I, and the firm is open to all indications including orphan and rare diseases.

The firm can work with all types of management teams and places more importance on their technology. The firm can both lead and co-invest along syndicates and will generally seek board representation in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: